Pan-cancer analyses of ACADM expression and its prognostic significance in the TCGA database. by Yu Zhang (12946)

Subjects:

Path analysis diagram illustrating the associations between alexithymia, social support, anticipated stigma and patient satisfaction, with their respective correlation coefficients... by Keya Bibikar (22386306)

General characteristics of study subjects. by Soo-Hee Hwang (17767519)

“…COVID-19 did not affect inpatient mortality (p = 0.9608), but in-hospital mortality decreased from 12% to 7% in the medical aid group.</p><p>Conclusion</p><p>Overall, we found that COVID-19 had an impact on admission rates of patients with AMI but did not have a significant impact on in-hospital mortality. …”

Active DNA Demethylation Mediated by <i>OsGADD45a2</i> Regulates Growth, Development, and Blast (Magnaporthe oryzea) Resistance in Rice by Ganghua Zhou (9283406)

Subjects:

P values of Kruskal–Wallis test at 95% significance level. by Fahd Saeed Alakbari (10701871)

Subjects:

Critical Role of Voltage Application Points in “Analog” and “Digital” Electrospray Ionization Mass Spectrometry by Min-Min Hung (21096009)

Subjects:

Critical Role of Voltage Application Points in “Analog” and “Digital” Electrospray Ionization Mass Spectrometry by Min-Min Hung (21096009)

Subjects:

Comparative Analysis of Chills Experience Across Three Groups: This table presents a detailed comparison of three groups (A, B, and C) in terms of their experiences with chills. It... by Felix Alexandre Schoeller (20988295)

Subjects:

<i>N. parisii</i> infection is not significantly changed in <i>C. elegans</i> sphingolipid biosynthesis mutants. by Hala Tamim El Jarkass (16625309)

Subjects:

Two-way ANCOVA results for Task 1. The bold values highlight statistically significant results of Task 1. by Mucahit Gemici (21519313)

One-way ANCOVA results for Task 2. The bold values highlight statistically significant results of Task 2. by Mucahit Gemici (21519313)

Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

Subjects:

Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

Subjects:

Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from clinical trials with psychotherapies. by Filip Stanicic (17808254)

Subjects:

Summary of clinical efficacy of relevant PTSD treatments. by Filip Stanicic (17808254)

Subjects: